Spots Global Cancer Trial Database for mfolfox6
Every month we try and update this database with for mfolfox6 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | NCT02563002 | Colorectal Carc... | mFOLFOX6 FOLFIRI pembrolizumab bevacizumab cetuximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | NCT03921684 | Rectal Cancer | Capecitabine Radiation thera... mFOLFOX6 Nivolumab | 18 Years - | Rabin Medical Center | |
| Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases | NCT02494973 | Colorectal Canc... | Oxaliplatin HAI Oxaliplatin IV mFOLFOX6 LV5FU2 | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 | NCT03618758 | Gastric Cancer ... Peritoneal Carc... Intraperitoneal... mFOLFOX6 | Paclitaxel mFOLFOX6 regime... | 20 Years - 79 Years | Seoul National University Bundang Hospital | |
| Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases | NCT01972490 | Colorectal Neop... | avastin mFOLFOX6 | 18 Years - 75 Years | Fudan University | |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
| Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) | NCT03130790 | Gastric Cancer | Varlitinib mFOLFOX6 Placebo mFOLFOX6 | 21 Years - | ASLAN Pharmaceuticals | |
| Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer | NCT00625651 | Metastatic Colo... Colon Cancer Colorectal Canc... Rectal Cancer | Placebo AMG 655 Modified FOLFOX... Bevacizumab | 18 Years - | Amgen | |
| A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis | NCT02102789 | Metastatic Colo... | mFOLFOX6 HAI | 18 Years - 70 Years | Sun Yat-sen University | |
| BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer | NCT01571024 | Advanced Solid ... Metastatic Colo... Metastatic Panc... | BKM120 mFOLFOX6 | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting | NCT02967289 | Colon Cancer (H... | Irinotecan Folfox Protocol | 18 Years - 75 Years | UNICANCER | |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | NCT05052801 | Gastric Cancer Gastroesophagea... | Bemarituzumab mFOLFOX6 Placebo | 18 Years - 100 Years | Amgen | |
| IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting | NCT02967289 | Colon Cancer (H... | Irinotecan Folfox Protocol | 18 Years - 75 Years | UNICANCER | |
| mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer | NCT03043729 | Rectal Cancer Rectosigmoid Ca... | Oxaliplatin 5-FU Leucovorin Aflibercept | 18 Years - | AIO-Studien-gGmbH | |
| mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer | NCT03043729 | Rectal Cancer Rectosigmoid Ca... | Oxaliplatin 5-FU Leucovorin Aflibercept | 18 Years - | AIO-Studien-gGmbH | |
| The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer | NCT04416854 | Metastatic Colo... Surgery | resection of pr... XELOX mFOLFOX6 | 18 Years - 75 Years | Fudan University | |
| Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer | NCT00625651 | Metastatic Colo... Colon Cancer Colorectal Canc... Rectal Cancer | Placebo AMG 655 Modified FOLFOX... Bevacizumab | 18 Years - | Amgen | |
| PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer | NCT03176264 | Metastatic Colo... | PDR001 bevacizumab mFOLFOX6 | 18 Years - | Novartis | |
| Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | NCT03921684 | Rectal Cancer | Capecitabine Radiation thera... mFOLFOX6 Nivolumab | 18 Years - | Rabin Medical Center | |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | NCT05052801 | Gastric Cancer Gastroesophagea... | Bemarituzumab mFOLFOX6 Placebo | 18 Years - 100 Years | Amgen | |
| Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 | NCT03618758 | Gastric Cancer ... Peritoneal Carc... Intraperitoneal... mFOLFOX6 | Paclitaxel mFOLFOX6 regime... | 20 Years - 79 Years | Seoul National University Bundang Hospital | |
| Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer | NCT03466424 | Radiation Oncol... Rectal Cancer | preoperative sh... | 18 Years - 70 Years | Fujian Medical University Union Hospital | |
| A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach | NCT02943603 | Adenocarcinoma Stomach Cancer | mFLOFOX6 + pemb... | 18 Years - 75 Years | University of Pittsburgh | |
| Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | NCT02648711 | Solid Tumors | CRLX101 Bevacizumab mFOLFOX6 | 18 Years - | Lumos Pharma | |
| A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis | NCT02102789 | Metastatic Colo... | mFOLFOX6 HAI | 18 Years - 70 Years | Sun Yat-sen University | |
| Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD) | NCT05427669 | Colorectal Canc... | mFOLFOXIRI mFOLFOX6 | 18 Years - 70 Years | Sun Yat-sen University | |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | NCT05052801 | Gastric Cancer Gastroesophagea... | Bemarituzumab mFOLFOX6 Placebo | 18 Years - 100 Years | Amgen | |
| Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases | NCT02494973 | Colorectal Canc... | Oxaliplatin HAI Oxaliplatin IV mFOLFOX6 LV5FU2 | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer | NCT00609622 | Colorectal Neop... | sunitinib mFOLFOX6 bevacizumab mFOLFOX6 | 18 Years - | Pfizer | |
| Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer | NCT05571644 | Colorectal Canc... | mFOLFOXIRI + Ca... mFOLFOX6 mFOLFOXIRI | 18 Years - 70 Years | Sun Yat-sen University | |
| PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors | NCT00819780 | Colon Cancer Colorectal Canc... Rectal Cancer Metastatic Colo... | Panitumumab Bevacizumab mFOLFOX6 | 18 Years - | Amgen | |
| A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | NCT03547999 | Metastatic Colo... | mFOLFOX6 MVA-BN-CV301 FPV-CV301 Nivolumab | 18 Years - | Hoosier Cancer Research Network | |
| A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | NCT04396821 | Advanced Cancer Gastric Cancer Gastroesophagea... Pancreatic Canc... | TST001 Nivolumab Injec... mFOLFOX6 Gemcitabine Albumin-Bound P... | 18 Years - | Suzhou Transcenta Therapeutics Co., Ltd. | |
| GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | NCT01332604 | Solid Cancers | GDC-0980 bevacizumab capecitabine mFOLFOX6 | 18 Years - | Genentech, Inc. | |
| A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | NCT03547999 | Metastatic Colo... | mFOLFOX6 MVA-BN-CV301 FPV-CV301 Nivolumab | 18 Years - | Hoosier Cancer Research Network | |
| Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | NCT02648711 | Solid Tumors | CRLX101 Bevacizumab mFOLFOX6 | 18 Years - | Lumos Pharma | |
| A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy | NCT01478594 | Colorectal Canc... | Tivozanib Bevacizumab mFOLFOX6 | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer | NCT05673772 | Rectal Cancer | short-course ra... mFOLFOX6 Chemoradiothera... TME surgery | 20 Years - 75 Years | Kyungpook National University Hospital | |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | NCT05174169 | Stage III Colon... | Signatera test mFOLFOX6 3-6 mo... CAPOX 3 month mFOLFIRINOX mFOLFOX6 6 mont... CAPOX 6 month | 18 Years - | NRG Oncology | |
| A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach | NCT02943603 | Adenocarcinoma Stomach Cancer | mFLOFOX6 + pemb... | 18 Years - 75 Years | University of Pittsburgh | |
| Cetuximab Monotherapy Maintenance Treatment in mCRC | NCT02978313 | Colorectal Canc... | Cetuximab mFOLFOX6 FOLFIRI | 18 Years - 75 Years | Ruijin Hospital | |
| CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II | NCT04120701 | Patients With R... | mFOLFOX6 | 18 Years - 75 Years | Centre Hospitalier Universitaire Dijon | |
| A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC | NCT05378867 | Metastatic Colo... | TRS003 China-approved ... mFOLFOX6 | 18 Years - | Zhejiang Teruisi Pharmaceutical Inc. | |
| FOLFOX6 Totally Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer: A Real World Study | NCT02887313 | Rectal Cancer | mFOLFOX6 Radiotherapy | 18 Years - 75 Years | Sun Yat-sen University | |
| Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation | NCT02580253 | Hepatocellular ... | Individualized ... mFOLFOX6 | 18 Years - 75 Years | Zhejiang University | |
| A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab | NCT01338558 | Colorectal Canc... | bevacizumab [Av... cetuximab mFOLFOX6 | 18 Years - | Hoffmann-La Roche | |
| Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) | NCT03130790 | Gastric Cancer | Varlitinib mFOLFOX6 Placebo mFOLFOX6 | 21 Years - | ASLAN Pharmaceuticals | |
| Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma | NCT01652976 | Pancreatic Canc... | Dasatinib mFOLFOX6 | 18 Years - | University of Florida | |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
| Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC | NCT05239650 | CRC | HLX07 HLX10 mFOLFOX6 | 18 Years - 75 Years | Shanghai Henlius Biotech | |
| Induction Chemotherapy for Locally Advanced Esophageal Cancer | NCT03110926 | Esophageal Carc... | mFOLFOX6 Chemoradiation | 18 Years - | University of Rochester | |
| Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) | NCT05008809 | Colorectal Canc... | mFOLFOX6 mFOLFOXIRI | 18 Years - | Charite University, Berlin, Germany | |
| Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients | NCT02510118 | Colon Cancer | mFOLFOX6 XELOX Placebo ChangTa... ChangTai Keli | 18 Years - 75 Years | Nanjing NingQi Medicine Science and Technology Co., Ltd. | |
| Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases | NCT01972490 | Colorectal Neop... | avastin mFOLFOX6 | 18 Years - 75 Years | Fudan University | |
| A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors | NCT00811993 | Neoplasms | RG1507 RO1507 bevacizumab [Av... capecitabine [X... carboplatin cetuximab docetaxel erlotinib [Tarc... etoposide gemcitabine irinotecan mFOLFOX6 paclitaxel pemetrexel sorafenib temozolomide trastuzumab [He... | 18 Years - | Hoffmann-La Roche | |
| A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis | NCT02102789 | Metastatic Colo... | mFOLFOX6 HAI | 18 Years - 70 Years | Sun Yat-sen University | |
| CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II | NCT04120701 | Patients With R... | mFOLFOX6 | 18 Years - 75 Years | Centre Hospitalier Universitaire Dijon | |
| GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | NCT01332604 | Solid Cancers | GDC-0980 bevacizumab capecitabine mFOLFOX6 | 18 Years - | Genentech, Inc. | |
| PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors | NCT00819780 | Colon Cancer Colorectal Canc... Rectal Cancer Metastatic Colo... | Panitumumab Bevacizumab mFOLFOX6 | 18 Years - | Amgen | |
| GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | NCT01332604 | Solid Cancers | GDC-0980 bevacizumab capecitabine mFOLFOX6 | 18 Years - | Genentech, Inc. | |
| Cetuximab Monotherapy Maintenance Treatment in mCRC | NCT02978313 | Colorectal Canc... | Cetuximab mFOLFOX6 FOLFIRI | 18 Years - 75 Years | Ruijin Hospital | |
| A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab | NCT01338558 | Colorectal Canc... | bevacizumab [Av... cetuximab mFOLFOX6 | 18 Years - | Hoffmann-La Roche | |
| CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II | NCT04120701 | Patients With R... | mFOLFOX6 | 18 Years - 75 Years | Centre Hospitalier Universitaire Dijon | |
| Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer | NCT05673772 | Rectal Cancer | short-course ra... mFOLFOX6 Chemoradiothera... TME surgery | 20 Years - 75 Years | Kyungpook National University Hospital | |
| Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC | NCT02942706 | Colorectal Canc... | Cetuximab mFOLFOX6 FOLFIRI | 18 Years - 75 Years | Ruijin Hospital | |
| IV Ascorbic Acid in Advanced Gastric Cancer | NCT03015675 | Gastric Cancer | ascorbic acid mFOLFOX6 | 18 Years - 75 Years | Sun Yat-sen University | |
| Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer | NCT00609622 | Colorectal Neop... | sunitinib mFOLFOX6 bevacizumab mFOLFOX6 | 18 Years - | Pfizer | |
| The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer | NCT04416854 | Metastatic Colo... Surgery | resection of pr... XELOX mFOLFOX6 | 18 Years - 75 Years | Fudan University | |
| Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC | NCT02942706 | Colorectal Canc... | Cetuximab mFOLFOX6 FOLFIRI | 18 Years - 75 Years | Ruijin Hospital | |
| Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer | NCT00609622 | Colorectal Neop... | sunitinib mFOLFOX6 bevacizumab mFOLFOX6 | 18 Years - | Pfizer | |
| Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer | NCT05571644 | Colorectal Canc... | mFOLFOXIRI + Ca... mFOLFOX6 mFOLFOXIRI | 18 Years - 70 Years | Sun Yat-sen University | |
| A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC | NCT05378867 | Metastatic Colo... | TRS003 China-approved ... mFOLFOX6 | 18 Years - | Zhejiang Teruisi Pharmaceutical Inc. | |
| BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer | NCT01571024 | Advanced Solid ... Metastatic Colo... Metastatic Panc... | BKM120 mFOLFOX6 | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer | NCT01889680 | Colorectal Canc... Metastatic Colo... | 5-FU LV ziv-aflibercept mFOLFOX6 | 18 Years - | NSABP Foundation Inc | |
| GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | NCT01332604 | Solid Cancers | GDC-0980 bevacizumab capecitabine mFOLFOX6 | 18 Years - | Genentech, Inc. | |
| Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer | NCT01889680 | Colorectal Canc... Metastatic Colo... | 5-FU LV ziv-aflibercept mFOLFOX6 | 18 Years - | NSABP Foundation Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
